Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creatio...Show More
peer of
competitor of
Metrics
marketSTOCKS
msh_idCOM:ACRIVON
localeus
websitehttps://acrivon.com/
ipo_date2022-11-15
primary_stock_msh_idNASDAQ:ACRV
source_refa419f731-17a2-4ffd-9b17-7b361d561418
products_or_servicesDevelopment of targeted therapies and precision oncology treatments utilizing the AP3 platform.